PharmaShots | Incisive News in 3 Shots

Subscribe Now

SUSTAIN study

Novartis Reports Positive Results of P-II SUSTAIN study for Crizanlizumab (SEG101) to Treat Sickle Cell Disease (SCD)

Novartis Reports Positive Results of P-II SUSTAIN study for Crizanlizumab (SEG101) to Treat Sickle Cell Disease (SCD)

October 10, 2018

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us